Cancer Treatments Advisory Committee

This advisory committee meets regularly to discuss applications to fund cancer medicines and advise Pharmac on the application.

On this page

Latest update

12 June 2026 | November 2025 Cancer Treatments Advisory Committee record added

5 June 2026 | New member to the Cancer Treatments Advisory Committee, Dr Michael Lau

3 June 2026 | Provisional recommendations for April 2026 meeting

26 May 2026

Agenda for Thursday 25 June added
Agenda for Friday 7 August added

Members of the Cancer Treatments Advisory Committee

Prof Stephen Munn – Transplant Surgeon (Chair, PTAC Member)
Dr Matthew Strother – Medical Oncologist (PTAC Member)
Dr Scott Babington – Radiation Oncologist
Dr Oliver Brake – Haematologist
Prof Christopher Frampton – Biostatistician
Dr Richard Isaacs – Medical Oncologist
Dr Allanah Kilfoyle – Haematologist
Dr Michael Lau – Anatomical Pathologist
Dr Vidya Mathavan – Haematologist
Dr Alice Minhinnick – Medical Oncologist
Dr Lochie Teague – Paediatric Haematologist / Oncologist
Dr Michelle Wilson – Medical Oncologist

2026 Committee meetings

Due to a high volume of funding applications, we have scheduled a series of meetings across 2026 for the Cancer Treatments Advisory Committee. These meetings will include both full-day and half-day sessions.

Agendas and provisional recommendations will be added as they are finalised.

Agenda for Thursday 30 April

Agenda for Thursday 25 June

Agenda for Friday 7 August

Thursday 17 September
Friday 6 November

More information about provisional recommendations

April 2026 CTAC meeting summary of provisional recommendations

Pharmaceutical and Indication	Provisional Recommendation
Alectinib(external link) for the treatment of resected, anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria	Medium priority
Durvalumab(external link) for the treatment of limited-stage, small cell lung cancer, within the context treatments for malignancy, subject to Special Authority criteria	High priority
Inavolisib(external link) for the treatment of HR-positive, HER2-negative, locally advanced or metastatic breast cancer, with a PIK3CA mutation, within the context treatments for malignancy, subject to Special Authority criteria	Medium priority
Ibrutinib(external link) for the treatment of mantle cell lymphoma, as an alternative to autologous stem cell transplant, within the context treatments for malignancy, subject to Special Authority criteria	High priority
Blinatumomab(external link) for the treatment of B-cell lineage acute lymphoblastic leukaemia (ALL), with no measurable residual disease (MRD-negative), within the context treatments for malignancy, subject to Special Authority criteria	High priority

Summary of provisional recommendations of the 30 April CTAC meeting [PDF, 85 KB]

March 2026 CTAC meeting summary of provisional recommendations

Pharmaceutical and indication	Provisional recommendation
Pertuzumab and trastuzumab(external link) for the adjuvant treatment of HER2-positive early breast cancer at high risk of recurrence, within the context for treatments for malignancy, subject to Special Authority criteria	*Withheld
Pertuzumab and trastuzumab(external link) widened access for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer with an ECOG status score 2-3, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Belzutifan(external link) for the treatment of tumours associated with Von-Hippel Lindau disease, within the context for treatments for malignancy, subject to Special Authority criteria	Medium priority
Eltrombopag(external link) widened access for the first line treatment of severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High priority
Eltrombopag(external link) widened access for the second-line treatment of relapsed/refractory severe aplastic anaemia in combination with immunosuppressive therapy, within the context for treatments for haematology, subject to Special Authority criteria	High Priority